RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on November 8 and set a price target of $12.00. The company’s shares closed yesterday at $5.13.
McNamara covers the Healthcare sector, focusing on stocks such as Danaher, Hologic, and Illumina. According to TipRanks, McNamara has an average return of -24.2% and an 8.62% success rate on recommended stocks.
Currently, the analyst consensus on Maravai Lifesciences Holdings is a Moderate Buy with an average price target of $10.00, representing a 94.93% upside. In a report released on November 8, Deutsche Bank also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Maravai Lifesciences Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $68.91 million and a GAAP net loss of $6.54 million. In comparison, last year the company earned a revenue of $242.73 million and had a net profit of $71.24 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Maravai Lifesciences Holdings (MRVI) Company Description:
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company’s segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers’ research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Read More on MRVI:
- Maravai LifeSciences Announces November 2023 Investor Conference Schedule
- Maravai Lifesciences price target lowered to $6 from $12 at UBS
- Maravai Lifesciences price target lowered to $7 from $11
- Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023
- Maravai LifeSciences Hosts 2023 Investor R&D Day
